Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESK981 + Nivolumab in mCRPC
NCT04159896Phase 2Terminated
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Nov 2019
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CEP-11981 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Barbara Ann Karmanos Cancer Institute. Started Nov 2019; status: terminated.
02
Drugs
CEP-11981
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04159896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04159896.